Jiangsu Hengrui Pharmaceuticals Co. Ltd. has patented new proteolysis targeting chimera (PROTACs) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to cyclin-dependent kinase 7 (CDK7) targeting moiety potentially useful for the treatment of cancer, inflammatory and autoimmune diseases.

Arvinas Inc. has identified new proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase coupled to a mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1)-targeting moiety acting as HPK1 degradation inducers designed for use in the treatment of cancer.

Haisco Pharmaceutical Group Co. Ltd. has disclosed new lysophosphatidic acid receptor 1 (LPAR1; EDG2) antagonists reported to be useful for the treatment of idiopathic pulmonary fibrosis.

Mayinglong Pharmaceutical Group Co. Ltd. has reported new 5-HT4 receptor agonists that are potentially useful for the treatment of gastroesophageal reflux disease, constipation, irritable bowel syndrome, dyspepsia, delayed gastric emptying (gastroparesis), intestinal pseudo-obstruction, diabetic gastroparesis and postoperative Ileus.

Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. has identified new molecular glue degrader compounds acting as proto-oncogene Vav (VAV1)/protein cereblon (CRBN) interaction inducers for degradation of VAV1 reported to be useful for the treatment of inflammatory bowel disease.

Scientists from Adlai Nortye Biopharma Co. Ltd. and Adlai Nortye Pte Ltd. have discovered new GTPase KRAS and/or GTPase KRAS (mutant) inhibitors that are potentially useful for the treatment of cancer, autoimmune disorders and inflammation.

Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have synthesized new protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.

Gluetacs Therapeutics (Shanghai) Co. Ltd. has discovered new proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN)-binding moiety coupled to a SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 2 (SMARCA2) and SMARCA4-targeting moiety. They are designed for use in the treatment of cancer, transplant rejection, infections, diabetes, autoimmune, neurological, inflammatory and cardiovascular disorders, among others.

Chengdu Diao Pharmaceutical Group Co. Ltd. has patented new 1,2,4-triazole compounds characterized as apelin receptor (APLNR) agonists. As such, they are described as useful for the treatment of obesity, hypertension, pulmonary hypertension, heart failure, diabetes, atherosclerosis, osteoporosis and sarcopenia.

Dovetree Medicines Unus Inc. has divulged new cellular tumor antigen p53 (TP53) (Y220C mutant) stabilizers potentially useful for the treatment of cancer.